Revenue
2012
2013
2022
2023
2024
2025
Relmada Therapeutics, Inc. (RLMD)
Price$4.43Cached quote
Net income
2012
2012
2013
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2013
2014
2015
2016
2017
2018
2019
2020
Total cash / debt
CashTotal debt
2012
2012
2013
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 · Dec 31 | 2019 · Jun 30 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 · Dec 31 | 2013 · Aug 31 | 2012 · Dec 31 | 2012 · Aug 31 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | $5,129 | — | $7,941 |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $1,093 | — | $2,142 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 21.31% | — | 26.97% |
| Research & development | $26.9M | $46.2M | $54.8M | $113.3M | $90.6M | $36.0M | $7.9M | $7.0M | $2.9M | $1.3M | $6.2M | $7.9M | $839,959 | $5.2M | — | $667,474 | — |
| Operating expenses | $59.1M | $83.9M | $103.7M | $161.2M | $125.7M | $60.8M | $15.1M | $12.7M | $6.9M | $7.2M | $16.2M | $17.1M | $12.9M | $6.8M | $46,108 | $3.2M | $14,194 |
| Operating income | −$59.1M | −$83.9M | −$103.7M | −$161.2M | −$125.7M | −$60.8M | −$15.1M | −$12.7M | −$6.9M | −$7.2M | −$16.2M | −$17.1M | −$12.9M | −$6.8M | −$45,015 | −$3.2M | −$12,052 |
| Operating margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | −877.66% | — | −151.77% |
| EBITDA | −$59.1M | −$83.9M | −$103.7M | −$161.2M | −$125.7M | −$60.8M | −$15.1M | −$12.7M | −$6.9M | −$7.1M | −$16.2M | −$17.1M | −$12.9M | −$6.8M | — | — | — |
| Net income | −$57.4M | −$80.0M | −$98.8M | −$157.0M | −$125.8M | −$59.5M | −$15.0M | −$17.3M | −$9.0M | −$6.3M | −$3.0M | −$20.8M | −$21.3M | −$19.9M | −$45,015 | −$6.9M | −$12,052 |
| Net profit margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | −877.66% | — | −151.77% |
| Basic EPSper basic share | -$1.45 | -$2.65 | -$3.28 | -$5.30 | -$7.16 | -$3.81 | -$1.62 | -$2.74 | -$2.86 | -$2.08 | -$1.04 | -$8.36 | -$34.60 | -$163.60 | $0.00 | -$63.40 | $0.00 |
| Diluted EPSper diluted share | -$1.45 | -$2.65 | -$3.28 | -$5.30 | -$7.16 | -$3.81 | -$1.62 | -$2.74 | -$2.86 | -$2.08 | -$1.04 | -$8.36 | -$34.60 | -$163.60 | $0.00 | -$63.40 | $0.00 |
Owners
Reported shareholders
10.47%of listed shares
Jupiter Topco LLC11.16M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Jupiter Topco LLC | 10.47%11.16M shares |
BlackRock, Inc. | 6.96%7.43M shares |
Squadron Capital Management LLC | 6.89%7.35M shares |
Venrock Adviser, LLC | 6.42%6.84M shares |
Spruce Street Capital LP | 5.99%6.39M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.47%4.76M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.18%4.46M shares |
Jones Hill Capital LP | 3.43%3.66M shares |
ORBIMED ADVISORS LLC | 3.40%3.63M shares |
STATE STREET CORP | 2.36%2.52M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.34%2.49M shares |
MILLENNIUM MANAGEMENT LLC | 2.21%2.36M shares |
MARSHALL WACE, LLP | 2.11%2.25M shares |
Ikarian Capital, LLC | 2.01%2.15M shares |
Driehaus Capital Management LLC | 2.00%2.13M shares |
AMERIPRISE FINANCIAL INC | 1.82%1.94M shares |
EVENTIDE ASSET MANAGEMENT, LLC | 1.74%1.86M shares |
Balyasny Asset Management L.P. | 1.43%1.52M shares |
STEMPOINT CAPITAL LP | 1.37%1.46M shares |
Commodore Capital LP | 1.34%1.43M shares |
Percentages use 106.67M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 15, 2025Form 4 | TRAVERSA SERGIOChief Executive Officer | BuyCommon Stock | 27.5K | $4.12 | $113.3K | 1.30M |
| Dec 15, 2025Form 4 | Shenouda MagedChief Financial Officer | BuyCommon Stock | 11.7K | $4.12 | $48.1K | 800.0K |
| Nov 5, 2025Form 4 | Ence ChuckCAO and COO | BuyCommon Stock | 136.0K | $2.20 | $299.2K | 403.9K |
| Nov 5, 2025Form 4 | TRAVERSA SERGIOChief Executive Officer | BuyCommon Stock | 272.5K | $2.20 | $599.5K | 1.27M |
| Nov 5, 2025Form 4 | Shenouda MagedChief Financial Officer | BuyCommon Stock | 500.0K | $2.20 | $1.10M | 788.3K |